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In Vivo Inhibition of Angiogenesis by
Interleukin-13 Gene Therapy in a
Rat Model of Rheumatoid Arthritis
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Angela Pakozdi,1 James M. Woods,2 Shiva Shahrara,3 and Alisa E. Koch4
Objective. Interleukin-13 (IL-13) is a pleiotropic
cytokine that can affect vessel formation, an important
component of the rheumatoid arthritis (RA) synovial
tissue pannus. The purpose of this study was to use a
gene therapy approach to investigate the role of IL-13 in
angiogenesis in vivo, using a rat adjuvant-induced ar-
thritis model of RA.
Methods. Ankle joints of female rats were injected
preventatively with an adenovirus vector containing
human IL-13 (AxCAIL-13), a control vector with no
insert (AxCANI), or phosphate buffered saline (PBS).
Joints were harvested at the peak of arthritis, and
histologic and biochemical features were evaluated.
Results. AxCAIL-13–treated joint homogenates
had lower hemoglobin levels, suggesting reduced joint
vascularity, and both endothelial cell migration and
tube formation were significantly inhibited (P < 0.05).
Similarly, AxCAIL-13 inhibited capillary sprouting in
the rat aortic ring assay and vessel growth in the
Matrigel plug in vivo assay. IL-13 gene delivery resulted
in up-regulation and association of phosphorylated
ERK-1/2 and protein kinase C/II, suggesting a novel
pathway in IL-13–mediated angiostasis. The angiostatic
effect of AxCAIL-13 was associated with down-
regulation of proangiogenic cytokines (IL-18, cytokine-
induced neutrophil chemoattractant 1/CXCL1,
lipopolysaccharide-induced CXC chemokine/CXCL5)
and up-regulation of the angiogenesis inhibitor endosta-
tin. The expression and activity of matrix metallopro-
teinases 2 and 9, which participate in angiogenesis, was
impaired in response to IL-13 as compared with Ax-
CANI and PBS treatment.
Conclusion. Our findings support a role for IL-13
as an in vivo antiangiogenic factor and provide a
rationale for its use in RA to control pathologic neovas-
cularization.
Angiogenesis is a highly orchestrated process
involving the sprouting of new capillary-like structures
from existing vasculature that mature into a system of
new blood vessels, resulting in neovascularization (1). It
can be triggered and modified by a number of factors,
including cytokines, chemokines, growth factors, and
matrix metalloproteinases (MMPs) (2). Angiogenesis is
central to many pathophysiologic conditions, such as
tumor growth, diabetic retinopathy, and rheumatoid
arthritis (RA) (1,3). The angiogenic process is often of
pivotal importance in the progression of disease and is
thus an interesting and promising therapeutic target (4).
Indeed, treatment of tumors and of RA in animal
models with vectors expressing interleukin-4 (IL-4),
IL-13, IL-10, and IL-1 antagonists using a gene therapy
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approach have shown success (5,6). Therefore, we inves-
tigated the possibility that IL-13 modulates arthritis
directly by inhibiting the angiogenic process.
IL-13 is a multifunctional cytokine with some
antiinflammatory effects in the context of inflammatory
arthritis (7). We have previously shown in rat adjuvant-
induced arthritis (AIA) that either human IL-13
(AxCAIL-13) or rat IL-13 (AxCArIL-13) administered
via an adenovirus vector profoundly reduced joint swell-
ing and local chemokine production (7). However, its
specific role and mechanisms in neovascularization re-
main unclear. What is known is that IL-13 signals
through type I cytokine receptors that form het-
erodimers and have binding domains for JAKs (8).
Accordingly, the biologic effects of IL-13 are often
mediated via the JAK/STAT pathway or via insulin
receptor substrate 1 (IRS-1) and IRS-2 on the IL-4
receptor subunit (9). However, recent studies suggest
that MAPK pathways may play a critical role in effector
responses of IL-13, including inflammation and tissue
remodeling (10,11), but their role in IL-13–mediated
effects on angiogenesis remains to be determined.
We have shown that IL-13 has both stimulatory
and inhibitory effects on endothelial cell (EC) migration
in vitro, a critical step in angiogenesis, pointing to a
dose-dependent phenomenon (12,13). Fukushi et al (14)
demonstrated that IL-13 significantly stimulated the
formation of tube-like structures by ECs in vitro and led
to corneal neovascularization in rats. In contrast, we
have previously shown that IL-13 not only reduced
inflammation, but also attenuated vascularization of the
synovium in AIA in the rat, an established model of RA
(7). Thus, to clarify the participation of IL-13 and to
elucidate its mechanism of action in joint inflammation,
we used a gene therapy approach to investigate the role
of IL-13 on angiogenesis in vivo, using rat AIA as a
model for neovascularization.
IL-13 inhibits the production of monocyte and
other cell-derived proinflammatory mediators, such as
cytokines, that in turn, can affect the angiogenic re-
sponse (9,15). Recently, we demonstrated that reduced
synovial vascularization in response to IL-13 gene deliv-
ery resulted in impaired joint levels of monocyte chemo-
tactic protein 1 (MCP-1) (7), a potent proangiogenic
chemokine (16,17). Among the various processes that
regulate angiogenesis, pericellular proteolysis is a pre-
condition for EC migration and capillary tube formation
in vivo (18,19), a process mainly regulated by MMPs.
Among the MMPs, the gelatinases MMP-2 and MMP-9
and the membrane-type MMPs have been suggested to
play a key role in angiogenesis (20,21).
In this study, we demonstrate that IL-13 gene
therapy inhibits angiogenesis in vivo by way of a novel
signaling pathway via protein kinase C/II (PKC/II)
and ERK-1/2. The angiostatic effect of IL-13 is associ-
ated with a shift in the balance of pro- and antiangio-
genic cytokines and decreased expression and activity of
MMP-2 and MMP-9.
MATERIALS AND METHODS
Preparation of adenovirus and experimental setup.
Replication-incompetent adenoviruses producing human
IL-13 (AxCAIL-13) or having no foreign gene insert (Ax-
CANI) were prepared, and AIA was induced in female Lewis
rats as described previously (7). AxCAIL-13 or rat
AxCArIL-13 was shown to successfully suppress arthritis clin-
ically (7). Rats were divided into 3 groups: one group received
AxCAIL-13, the second received AxCANI (control), and the
third received phosphate buffered saline (PBS; control). The
AxCANI group was included to distinguish between the effects
of the adenovirus and the effects of the IL-13. On day 8 after
AIA induction, prior to development of arthritis, PBS or 5 
106 plaque-forming units of either AxCAIL-13 or AxCANI was
administered to each hind ankle via intraarticular injection. All
animals were euthanized on day 18 after adjuvant injection, at
the peak of inflammation, and the ankles were collected for
further analysis.
Preparation of ankle homogenates and determination
of hemoglobin and protein concentrations. For angiogenesis
assays, rat joints were homogenized as described previously
(22). Hemoglobin levels were measured by the tetramethylben-
zidine method. A bicinchoninic acid assay (BCA Protein Assay
kit; Pierce, Rockford, IL) was used to determine protein
concentrations.
Cell culture. Human dermal microvascular endothelial
cells (HMVECs; Cambrex, Walkersville, MD) were main-
tained in EC basal medium (EBM) supplemented with 10%
fetal bovine serum (FBS) and additional growth factors (Cam-
brex) at 37°C in an atmosphere of 5% CO2. Cells between
passages 5 and 12 were used for angiogenesis assays. For some
studies, human U937 cells were cultured for signal transduc-
tion studies. Briefly, U937 cells were cultured in suspension to
106 cells/ml in T175 flasks with 10% FBS in RPMI 1640
containing penicillin and streptomycin.
In vitro migration of HMVECs. HMVEC in vitro
migration was determined using a modified 48-well Boyden
chamber as previously described (2). Pooled joint homoge-
nates from 5 rats (60 g of protein/ml), PBS, or positive
control basic fibroblast growth factor (bFGF; 60 nM) were
used as stimulant. Each assay was run in quadruplicate, and the
results were expressed as the number of HMVECs migrating
per high-power field (hpf; 40 magnification).
For some studies, neutralizing antibody to human
IL-13 was incubated with pooled ankle homogenates obtained
on day 18 from AxCAIL-13–treated rats to evaluate inhibition
of HMVEC migration due solely to human IL-13. AxCAIL-
13–treated rat joint homogenates (60 g/ml) were used in all
samples, and homogenates were combined with either normal
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mouse IgG or neutralizing mouse anti-human IL-13 antibody
(10 g/ml respectively; R&D Systems, Minneapolis, MN).
HMVECs and homogenates were added to the Boyden
chambers, and the numbers of migrating cells were counted
after a 2-hour incubation period.
In vitro capillary morphogenesis assay. Tube forma-
tion by HMVECs in growth factor–reduced (GFR) Matrigel
was used to evaluate the effect of AxCAIL-13–treated rat joint
homogenates on capillary morphogenesis, as previously de-
scribed (23). Eight ankle homogenates per group (60 g of
protein/ml) were tested as stimulant. Phorbol myristate acetate
(PMA; 50 nM) and DMSO served as controls. After 16–18
hours, capillary morphogenesis was examined under a phase-
contrast microscope, and node formation (defined as a nodular
contact formation of at least 3 adherent endothelial cell tubes)
was evaluated blindly. The assay was performed 3 times.
Growth assay for rat aortic ring microvessel sprouting.
Aortas from female Sprague-Dawley rats (100 gm) were
Figure 1. Inhibition of angiogenesis in joint homogenates from rats with adjuvant-induced arthritis (AIA) treated with
AxCAIL-13. A, Hemoglobin levels were measured in ankle homogenates and normalized to the total joint protein content.
Hemoglobin levels were significantly lower following AxCAIL-13 treatment as compared with phosphate buffered saline (PBS)
and AxCANI, which emphasizes the angiostatic effect of interleukin-13 (IL-13) in vivo. Values are the mean and SEM of (n
 number of joint homogenates). B, AxCAIL-13 joint homogenates significantly inhibited human dermal microvascular
endothelial cell (HMVEC) migration compared with PBS and AxCANI homogenates. Values are the mean and SEM (n 
number of assays). HMVEC migration in response to PBS alone (mean  SEM 54.4  7.2 cells/high-power field [hpf]) or to
60 nM basic fibroblast growth factor (112.8  14.1 cells/hpf) served as negative and positive controls, respectively (data not
shown). C, Neutralizing antibody against IL-13 reversed the inhibition of HMVEC migration by ankle homogenates obtained
on day 18 from AxCAIL-13–treated rats. AxCAIL-13 joint homogenates (60 mg/ml) were the chemoattractant in all samples.
Homogenates were combined with 10 g/ml of either normal mouse IgG or neutralizing mouse anti-human IL-13 before
addition to Boyden chambers containing HMVECs. Values are the mean and SEM (n  number of assays). D, Rat AIA joint
homogenate–induced EC tube formation in an in vitro Matrigel assay was inhibited by IL-13 gene therapy. Values are the mean
and SEM (n  number of plugs per group). Inset, Representative photomicrographs showing EC tube formation in the 3
treatment groups (original magnification  40).
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dissected and sliced into 1-mm–thick rings (24). Aortic rings
were placed into 300 l of GFR Matrigel in 48-well plates.
Serum-free EBM medium (300 l) with pooled joint homog-
enates (60 g of protein/ml) from rats with AIA was added and
replaced 3 times each week. PMA (50 nM) and DMSO were
used as positive and negative controls, respectively. Microves-
sel sprouting from the adventitial layer was assessed and
scored using the following scale (25): 0  no sprouting, 0.25 
isolated sprouting, 0.5  sprouting in 20–50% of the arterial
circumference, 1  sprouting in 50–75% of the circumference,
1.5  sprouting in 100% of the circumference, and 2  100%
of the arterial circumference occupied by sprouts longer than
one-third of the length of the average radius of the rings.
Matrigel plug in vivo angiogenesis assay. To examine
the effects of AxCAIL-13 treatment on angiogenesis in vivo,
Matrigel plug assays were performed as previously described
(26). GFR Matrigel containing either pooled joint homoge-
nates (120 g of protein/ml) from rats with AIA, PBS, or
bFGF (1 ng/ml) was injected subcutaneously into female
C57BL/6 mice. After 7 days, the plugs were dissected, homog-
enized, and analyzed. Hemoglobin and protein levels were
measured as described above. In some experiments, Matrigel
(500 l) containing homogenates from rat ankles treated with
AxCAIL-13 or AxCANI (120 g/ml of protein) was injected
subcutaneously into the C57BL/6 mice. After 7 days, the
Matrigel plugs were removed, embedded in OCT, cryosec-
tioned, and stained with Diff-Quick, and the number of blood
vessels was counted by an observer (MAA) who was blinded to
the experimental setup.
Enzyme-linked immunosorbent assays (ELISAs) for
rat cytokines and growth factors. Commercially available
ELISA kits detecting the following proteins were used to
determine possible mediators or inhibitors of angiogenesis in
joint homogenates from rats with AIA: fractalkine/CX3CL1,
cytokine-induced neutrophil chemoattractant 1 (CINC-1)/
CXCL1, lipopolysaccharide-induced CXC chemokine (LIX)/
CXCL5, IL-6, IL-18, endostatin, and the total (latent plus
active) amount of transforming growth factor  (TGF). The
sensitivity of these ELISAs is routinely 15 pg/ml. Levels of
CXCL16 were analyzed by a sandwich ELISA (27), with a
sensitivity of 125 pg/ml.
Western blot analysis and immunoprecipitation.
Equal protein amounts of rat AIA joint homogenates were
subjected to 10% sodium dodecyl sulfate (SDS) gel electro-
phoresis, transferred onto nitrocellulose membranes, and sub-
jected to Western blot analysis as previously described (28),
using the following rabbit anti-human antibodies to selected
phosphorylated (*p) signaling molecules (all from Cell Signal-
ing Technology, Beverly, MA): anti–*p–ERK-1/2, anti-
*pJAK1, anti–*p-JNK, anti–*p–NF-B p65, anti–*p–p38
MAPK, anti-*pp70S6K, anti–*p-PKC/II, anti–*p-Raf, anti–
*p-Src, anti-*pSTAT1, and anti-*pSTAT6. Subsequently, blots
were reprobed with rabbit antiactin (Sigma, St. Louis, MO) or
anti–total NF-B (Santa Cruz Biotechnology, Santa Cruz, CA)
antibody. Bands were scanned, and their intensities were
analyzed with Un-Scan-It software version 5.1 (Silk Scientific,
Orem, UT). Immunoprecipitation was performed as described
previously (29), using antiphosphotyrosine or anti–ERK-1/2
(Cell Signaling Technology), followed by immunoblotting.
To further understand and authenticate the mecha-
nism through which IL-13 modulation of the signaling mole-
cules inhibits inflammation and angiogenesis in the joints of
the treated rats, we used the U937 monocytic cell line to study
the effects of IL-13 on the phosphorylation of the proteins of
interest. Monocyte/macrophages are producers of many potent
angiogenic mediators in the human RA joint (30,31). U937
cells (1  106/ml) in 6-well plates in 5% FBS/RPMI 1640 were
treated or were not treated with recombinant human IL-13 at
a concentration range of 2.5–20 ng/ml for 20 minutes. Cells
were lysed in lysis buffer (100 mM Tris, pH 7.4, 100 mM NaCl,
1 mM EDTA, 1 mM EGTA, 1 mM NaF, 20 mM NaH2PO4, 2
mM Na3VO4, 1% Triton X-100, 10% glycerol, 0.1% SDS, 0.5%
deoxycholate, 1 mM phenylmethylsulfonyl fluoride) and pro-
tease inhibitors (1 tablet/10 ml; Roche Diagnostics, Indianap-
olis, IN), and protein was measured using BCA Protein Assay
kits (Pierce, Rockford, IL). Equal amounts of protein (20 g)
were separated by SDS–polyacrylamide gel electrophoresis
and transferred onto nitrocellulose membranes (Bio-Rad).
Western blot analysis was performed as previously described
(28).
Gelatin zymography and immunofluorescence. MMP
activity in homogenates from rats with AIA was identified by
gelatin zymography. MMP-2 and MMP-9 activity presented as
digested unstained bands on the gelatin gels, according to the
molecular weights of proMMP-9 (92 kd), proMMP-2 (72 kd),
and active MMP-9 (62 kd). Photographs were taken with a
Nikon Coolpix 4500 digital camera (Nikon, Melville, NY). For
immunofluorescence studies, HMVECs were plated overnight
at 20,000 cells/well in 8-well chamber slides in EBM with 5%
FBS. Cells were serum-starved for 1 hour and stimulated with
joint homogenates from rats with AIA (30 g protein/ml) for
0, 5, and 30 minutes and analyzed using goat anti–MMP-2 or
anti–MMP-9 antibodies (Santa Cruz Biotechnology) and Alexa
Fluor 488–conjugated secondary antibody (Invitrogen, Carls-
bad, CA). Images were taken using an Olympus BX51 Fluo-
rescence Microscope System with DP Manager imaging soft-
ware (Olympus, Lake Success, NY).
Statistical analysis. Data are reported as the mean 
SEM. For statistical purposes, each ankle was treated indepen-
dently, since AIA in rats often develops independently in each
ankle (22). Statistical analysis was performed using Student’s
t-test. P values less than 0.05 were considered statistically
significant.
RESULTS
Reduced numbers of functional vessels in vivo
following IL-13 gene delivery in rats with AIA. To
determine if IL-13 gene delivery reduces vascularity in
the joints of rats with AIA, hemoglobin levels, which are
proportional to the number of functional vessels in the
tissue, were measured in ankle homogenates (Figure
1A). Hemoglobin levels were significantly lower in the
AxCAIL-13 group (mean  SEM 0.11  0.01 gm/dl per
mg of protein) than in the PBS and AxCANI groups
(0.93  0.08 and 1.03  0.12, respectively; P  0.05 for
each comparison).
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Inhibition of in vitro EC migration following
IL-13 gene delivery. We first tested in vitro whether joint
homogenates from rats with AIA induce EC migration,
a crucial step in the process of neovascularization, and
whether IL-13 gene therapy is able to impair this effect
(Figure 1B). HMVEC migration in response to homog-
enates from PBS-treated AIA rats was 2-fold higher
than baseline and was in the range of migration in
Figure 2. Inhibition of angiogenesis ex vivo and in vivo by AxCAIL-13. To assess the effect of AxCAIL-13 gene therapy on
complex angiogenic processes, a rat aortic ring assay and a Matrigel angiogenesis in vivo plug assay were performed. A, Vessel
sprouting induced by joint homogenates from rats with adjuvant-induced arthritis (AIA), starting after 10 days, was inhibited
by AxCAIL-13, but not AxCANI or phosphate buffered saline (PBS). Values are the mean of 8 aortic rings per group. B, Sprout
formation on day 28 was significantly less responsive to AxCAIL-13–treated rat AIA joint homogenates than to AxCANI–
treated joint homogenates. Values are the mean and SEM (n  number of joint homogenates). Inset, Representative
photomicrographs showing vessel sprouting in the 3 treatment groups (original magnification  40). Phorbol myristate
acetate–induced sprouting (mean  SEM score 0.94  0.39; n  4) was similar to that in the PBS and AxCANI group, and was
significantly higher than that with DMSO (score of 0.06  0.06; n  4 [P  0.05]) (data not shown). C, In the Matrigel
angiogenesis in vivo plug assay, hemoglobin levels in response to AxCAIL-13 (0.37  0.06 gm/dl per mg of plug weight) were
significantly lower than those in response to PBS and AxCANI, but were similar to those with Matrigel plugs and only PBS
(negative control; score of 0.38  0.21) (data not shown). Values are the mean and SEM (n  number of mice). D, To further
address the antiangiogenic properties of interleukin-13 (IL-13) gene therapy in vivo, Matrigel (500 l) containing homogenates
obtained on day 18 from rat ankles treated with human AxCAIL-13 or AxCANI (120 g/ml of protein) was subcutaneously
injected into C57BL/6 mice. After 7 days, Matrigel plugs were removed, embedded in OCT, cryosectioned, stained with
Diff-Quick, and blood vessels were counted. Plugs containing AxCAIL-13 homogenates showed significantly less blood vessel
development than did those containing AxCANI homogenates. Values are the mean and SEM (n  number of mice).
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response to bFGF (data not shown). HMVEC chemo-
taxis in vitro in response to AxCANI (mean  SEM
96.8  7.1 cells/3 hpf) was comparable to the effect
induced by the PBS homogenates (103.5  3.6), whereas
AxCAIL-13 significantly inhibited the migratory re-
sponse compared with both groups (52.0  6.6; P 
0.05), suggesting that IL-13 gene delivery inhibits EC
migration.
We further tested the effects of neutralizing
antibody against human IL-13 to see if this would
reverse the inhibition of HMVEC migration by day 18 in
AxCAIL-13–treated rat ankle homogenates. This would
show specificity of human IL-13 to directly inhibit
HMVEC chemotaxis in vitro. As shown (Figure 1C),
AxCAIL-13–treated rat joint homogenates incubated
with nonspecific mouse IgG reduced HMVEC chemo-
taxis, as measured in a modified Boyden chemotaxis
system. However, homogenates combined with neutral-
izing mouse anti-human IL-13 abrogated the inhibitory
effect, demonstrating that inhibition of angiogenesis by
IL-13 can be reversed by neutralization of human IL-13
in vitro. These results indicate that inhibition of HM-
VEC chemotaxis can be directly attributed to IL-13
expression. Negative and positive controls were PBS
(8.9  0.7 cells/3 hpf) and bFGF (16.8  1.2 cells/3 hpf),
respectively. Results are expressed as the fold increase
compared with control IgG.
AxCAIL-13–induced reduction of EC tube forma-
tion in an in vitro capillary morphogenesis assay. To
examine the role of in vivo IL-13 gene therapy on EC
differentiation, another important step in angiogenesis,
we studied EC tube formation in an in vitro capillary
morphogenesis assay in response to PBS-, AxCANI-,
and AxCAIL-13–treated joint homogenates from rats
with AIA (Figure 1D). Joint homogenate–induced tube
formation (mean  SEM 65.5  3.2 nodular tube
contacts) was not altered by AxCANI (61.8  2.2), but
AxCAIL-13 treatment resulted in a joint environment
that significantly impaired EC tube formation (23.4 
3.1; P  0.05). These data imply that IL-13 gene delivery
opposes EC differentiation.
AxCAIL-13–induced inhibition of vessel sprout-
ing stimulated by joint homogenates from rats with AIA,
by aortic ring assay. To confirm the in vitro data and to
test the effect of AxCAIL-13 on the concerted action of
both EC migration and differentiation, we next per-
formed a rat aortic ring assay to determine whether joint
homogenates from rats with AIA treated with
AxCAIL-13 are less likely than control AxCANI-treated
or PBS-treated homogenates to promote EC sprouting
(Figures 2A and B). EC sprout formation started after
10 days in the PBS group, constantly increasing until
day 28, thereby confirming that rat AIA joint homoge-
nates have proangiogenic properties in this assay. While
treatment with AxCANI did not alter the extent of
sprout formation, no significant sprouting was observed
with AxCAIL-13 joint homogenates (Figure 2A). In-
deed, on day 28, sprout formation scores in the
AxCAIL-13 group were significantly reduced in compar-
ison with the AxCANI group (mean  SEM score
0.28  0.19 versus 1.06  0.24; P  0.05) and tended to
be higher than in the PBS group (Figure 2B). PMA-
induced sprouting (score of 0.94  0.39) was comparable
to that in the PBS and AxCANI group and was signifi-
cantly higher than that in the DMSO group used as a
negative control (score of 0.06  0.06; P  0.05) (data
not shown).
AxCAIL-13–induced inhibition of angiogenesis
in vivo. To further evaluate the antiangiogenic effects of
IL-13 gene therapy in an in vivo setting, we performed a
Matrigel plug in vivo angiogenesis assay, in which hemo-
globin levels are determined in order to assess the extent
of blood vessel penetration and formation in response to
stimulus (Figure 2C). The hemoglobin content of the
PBS-treated ankle homogenates (mean  SEM 0.71 
0.15 gm/dl per mg of plug weight) was increased 1.9-
fold as compared with Matrigel plugs containing only
PBS (data not shown), but was similar to that in the
AxCANI group (0.60  0.12 gm/dl per mg of plug
weight). AxCAIL-13 treatment resulted in significantly
decreased hemoglobin levels (0.37  0.36 gm/dl per mg
of plug weight; P  0.05), suggesting an important role
in the inhibition of blood vessel growth in arthritis in
vivo.
To examine actual vessel growth in vivo, Matrigel
(500 l) containing day 18 homogenates from rat ankles
treated with either human AxCAIL-13 or AxCANI (120
g/ml of protein) was subcutaneously injected into
C57BL/6 mice. Matrigel plugs containing AxCAIL-13
homogenates showed significantly less blood vessel de-
velopment as compared with the plugs containing Ax-
CANI homogenates (P  0.05) (Figure 2D).
Activation of PKC/II and ERK-1/2 following
IL-13 gene therapy. To identify possible signaling path-
ways involved in IL-13–mediated antiangiogenic effects
in vivo, we analyzed the expression of different phos-
phorylated signaling molecules in rat AIA joint homog-
enates, using immunoprecipitation and immunoblotting
techniques (29) (Figure 3 and Table 1). We studied the
expression of *p-Tyk2 and *pSTAT6, signaling mole-
cules known to be activated by IL-13, by immunopre-
cipitation and/or immunoblotting techniques. Both *p-
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Figure 3. Induction of ERK-1/2 and protein kinase C (PKC) phosphorylation by interleukin-13 (IL-13) gene therapy. A, Immunoprecipitation (IP)
of total ankle homogenates with phosphotyrosine and subsequent Western blotting (WB) for Tyk2 showed a significant up-regulation of *p-Tyk2
in response to IL-13 gene therapy in vivo. B, AxCAIL-13 increased the amount of *p–ERK-1/2 as compared with phosphate buffered saline (PBS)
and AxCANI, as determined by immunoblotting. C, AxCAIL-13 treatment resulted in up-regulation of *p-PKC/II, as determined by Western
blotting. Values in A–C are the mean and SEM (n  number of joint homogenates). D, Immunoprecipitation with ERK-1/2 and immunoblotting
with *p-PKC/II showed up-regulation in the AxCAIL-13 group, suggesting an association between the 2 signaling molecules. Joint homogenates
from rats with adjuvant-induced arthritis were used for the studies shown in A–D. E, Recombinant human IL-13 (rhIL-13) dose-dependently induced
the phosphorylation of Tyk2, ERK-1/2, and PKC/II in U937 monocytic cells. Western blots shown are representative of 3 independent
experiments.
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Tyk2 and *pSTAT6 were significantly increased in
response to IL-13 gene therapy as compared with Ax-
CANI or PBS treatment (Figure 3A and Table 1). Of
note, we found a strong up-regulation of *p–ERK-1/2
and *p-PKC/II in the AxCAIL-13 group (Figures 3B
and C). In addition, up-regulation of *p-Raf (Table 1)
emphasized the notion of an IL-13–mediated activation
of the ERK-1/2 pathway. The expression of *p-Akt,
*p-Src, *pJAK1, *p-JNK, *p–p38 MAPK, *pp70S6K,
and *pSTAT1 were unchanged. Interestingly, the ex-
pression of *p–NF-B p65 was significantly down-
regulated, indicating reduced transcription activity via
NF-B, and *pSTAT1 expression was not modified in
response to AxCAIL-13 (Table 1).
To test whether the phosphorylation steps of
ERK-1/2 and PKC/II are associated in a common
pathway due to in vivo IL-13 gene therapy, joint homog-
enates from rats with AIA were immunoprecipitated
with anti–ERK-1/2, followed by immunoblotting for
select proteins. Of note, *p-PKC/II was up-regulated
in the AxCAIL-13 group as compared with the PBS and
AxCANI groups (Figure 3D), whereas no association
was observed with *p-Tyk2 and *pSTAT6 (results not
shown). These data indicate a novel signaling pathway
involving ERK-1/2 and PKC/II in IL-13–mediated
antiangiogenesis in vivo.
In order to confirm the in vivo findings and test
whether IL-13 similarly induces phosphorylation of
Tyk2, ERK-1/2, and PKC/II, as observed in the joint
homogenates from the rats treated with AxCAIL-13,
U937 cells were treated with various concentrations of
human IL-13. Western blot analysis showed that IL-13
induces the activation of *p-Tyk2, *p–ERK-1/2, and
*p-PKC/II in a concentration-dependent manner
(Figure 3E). These results were similar to the expression
profiles of the same proteins observed in the joint.
Altered expression of pro- and antiangiogenic
mediators in vivo following preventative IL-13 gene
therapy. To determine if IL-13 gene delivery indirectly
mediates its angiostatic effects through anti- or pro-
angiogenic mediators, we analyzed by ELISA the pro-
tein expression of select cytokines, chemokines, and
growth factors in joint homogenates obtained on day 18
from rats with AIA (Figure 4). LIX/CXCL5, the rat
homolog of angiogenic epithelial neutrophil–activating
peptide 78 (ENA-78)/CXCL5, was strongly down-
regulated by AxCAIL-13, implying that this chemokine
may contribute to mediating the proangiogenic effects.
Similarly, levels of CINC-1/CXCL1, the rat homolog of
angiogenic growth-related oncogene  (GRO)/
CXCL1, were significantly lower in the AxCAIL-13
group (Figures 4A and B). In addition, IL-18, a cytokine
with strong proangiogenic properties, was down-
regulated in response to IL-13 gene therapy, an effect
that was significant as compared with AxCANI, while
Table 1. Densitometry of Western blots detecting signaling molecule expression in
ankle joint homogenates from rats with adjuvant-induced arthritis preventatively






*p–ERK-1/2 0.59  0.02 (4) 1.93  0.17 (4)†
*p-PKC/II 0.57  0.01 (4) 0.80  0.02 (3)†
*p-Raf 0.024  0.003 (4) 0.073  0.015 (3)†
*pSTAT6 0.44  0.01 (5) 0.97  0.02 (5)†
*p-Tyk2 0.11  0.02 (4) 0.32  0.08 (4)†
Unchanged signaling molecules
*p-Akt 0.09  0.03 (4) 0.19  0.05 (4)
*p-Src 0.16  0.01 (4) 0.28  0.06 (3)
*pJAK1 0.03  0.004 (4) 0.025  0.007 (3)
*p-JNK 0.30  0.03 (4) 0.20  0.04 (3)
*p–p38 MAPK 0.07  0.02 (4) 0.04  0.01 (4)
*pp70S6K 0.04  0.003 (3) 0.03  0.005 (4)
*pSTAT1 0.37  0.04 (5) 0.45  0.03 (5)
Down-regulated signaling molecules
*p–NF-B p65 0.38  0.05 (3) 0.10  0.02 (4)
* Joint homogenates obtained on day 18 were used for all Western blot analyses.
Values are the mean  SEM ratio of signaling molecule to actin; values in
parentheses are the number of ankles. PKC/II  protein kinase C/II.
† P  0.05 versus AxCANI-injected group.
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Figure 4. Altered balance of pro- and antiangiogenic mediators following interleukin-13 (IL-13) gene therapy. A and B, Expression of
lipopolysaccharide-induced CXC chemokine (LIX)/CXCL5 and cytokine-induced neutrophil chemoattractant 1 (CINC-1)/CXCL1, the rat homologs
of epithelial neutrophil–activating peptide 78/CXCL5 and growth-related oncogene /CXCL1, respectively, was significantly lower in the
AxCAIL-13 group, although AxCANI alone increased the levels of both chemokines as compared with phosphate buffered saline (PBS). C and D,
IL-18, a cytokine with strong proangiogenic properties, but not IL-6, was significantly down-regulated by AxCAIL-13. E and F, Expression of the
proangiogenic membrane-associated chemokines CXCL16 and fractalkine was not affected by AxCANI or AxCAIL-13. G and H, AxCAIL-13
induced the expression of transforming growth factor  (TGF), but also resulted in significantly higher endostatin levels, as compared with
AxCANI. Values are the mean and SEM (n  number of joint homogenates).
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the expression of IL-6, which is possibly proangiogenic
(32), was not affected (Figures 4C and D).
Levels of the membrane-bound chemokines
CXCL16 and fractalkine, both of which are known to
promote neovascularization, were not altered by
AxCAIL-13 (Figures 4E and F). TGF, a bifunctional
regulator of angiogenesis, was up-regulated, an effect
that was significant compared with AxCANI (Figure
4G). Expression of the angiogenesis inhibitor endostatin
was also significantly increased in AxCAIL-13–treated
joint homogenates as compared with the vector control
AxCANI, whereas application of the adenovirus vector
without the insert resulted in a down-regulation of
endostatin expression (Figure 4H).
Down-regulation of MMP-2 and MMP-9 by in
vivo IL-13 gene delivery. To investigate whether IL-13
may exert its in vivo angiostatic effects in part via
MMP-2 and MMP-9, joint homogenates from PBS-,
AxCANI-, and AxCAIL-13–treated rats with AIA were
analyzed by gelatin zymography (Figure 5). The gelati-
nase activity was clearly down-regulated by IL-13 gene
therapy as compared with AxCANI (Figures 5A and B),
whereas it was comparable in both the AxCANI and the
PBS group (data not shown). Protein expression of
MMP-2 and MMP-9 on HMVECs stimulated with rat
AIA homogenates showed similar results, with intracell-
ular down-regulation of both gelatinases (Figure 5C).
DISCUSSION
Neovascularization is a hallmark of various dis-
eases and a characteristic feature of the joint synovial
tissue in RA and is critical for disease progression (30).
AIA in the rat is an inflammatory disease associated
with neovascularization and has been used to study
angiogenesis (33,34). Gene therapy presents an appeal-
ing approach to the study of the pathophysiologic mech-
anisms in vivo and has been proven to be useful in
studying angiogenesis in various animal models (35–39).
In addition, it has been shown that genes encoding
antiarthritic properties can be transferred to specific in
vivo sites and alter inflammatory responses (40).
Several genes showing promise for use in gene
therapy for RA include IL-4, IL-1 receptor antagonist
protein, IL-1, TNF soluble receptors, TGF, and IL-13,
among others (22,40). With regard to IL-13 expression,
we and other investigators have shown that IL-13 di-
rectly down-regulates arthritis and inflammatory re-
sponses in the joints of rodent models of RA (7,41). In
addition, we previously showed that IL-13 expression
attenuated MMP-mediated cartilage degradation in an
Figure 5. Down-regulation of matrix metalloproteinase 2 (MMP-2)
and MMP-9 activity in vivo following interleukin-13 (IL-13) gene
therapy. A, Zymography showing down-regulation of proMMP-2 (72
kd), active MMP-2 (62 kd), and MMP-9 (92 kd) in AxCAIL-13–treated
joint homogenates from rats with adjuvant-induced arthritis (AIA). B,
Quantification of gelatinase activity as determined by densitometry,
confirming the reduction of MMP-2 and MMP-9 levels following
AxCAIL-13 treatment. Gelatinase activity of both AxCANI– and
phosphate buffered saline (PBS)–treated homogenates was compara-
ble (data not shown). Values are the mean and SEM (n  number of
joint homogenates). C, Immunofluorescence staining of human dermal
microvascular endothelial cells stimulated with joint homogenates
from rats with AIA, showing somewhat decreased expression of
MMP-2 and MMP-9 proteins in the AxCAIL-13 group. IgG served as
negative control. Photomicrographs are representative of 2 indepen-
dent experiments (original magnification 400).
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immune complex model of RA, explaining in part, the
antiinflammatory properties of IL-13 (42). In the current
study, we investigated the possibility that IL-13 also
functions as an antiangiogenic mediator in the arthritic
joint.
In an earlier study, we demonstrated that IL-13
delivered by gene therapy into the joints of rats with AIA
results in decreased synovial blood vessel numbers (7).
However, it was unclear if IL-13 directly inhibits the de
novo growth of blood vessels in the arthritic joint, or
whether it takes on an indirect role by down-regulating
angiogenic mediators. For instance, Bessis et al (43)
previously showed that IL-13 decreases the expression of
human TNF in a transgenic murine model. Their
findings suggest that IL-13 acts in part to modulate
angiogenesis by inhibiting the production of proangio-
genic cytokines. Interestingly, in vitro analysis of IL-13
has shown it to exert both pro- and antiangiogenic
properties dose-dependently (12,13). To clarify these
issues, we evaluated the effect of IL-13 gene therapy on
neovascularization in vivo, using rat AIA as a model of
pathologic blood vessel growth and joint inflammation.
We initially determined hemoglobin levels in the
joints of rats with AIA as a reflection of the density of
functional blood vessels in the synovium. Decreased
hemoglobin content in response to AxCAIL-13 is sug-
gestive of antiangiogenic properties of IL-13 in vivo
(Figure 1A). First, we showed in vitro that rat AIA joint
homogenate–induced EC migration was significantly
inhibited by AxCAIL-13 (Figure 1B), suggesting a net
angiostatic effect of in vivo IL-13 gene delivery. We used
day 18 AxCAIL-13 homogenates, since these have pre-
viously been shown to express elevated levels of IL-13
for at least 10 days after delivery (7), and we compared
them with day 18 AxCANI homogenates. Because EC
migration was not affected by AxCANI, the antimigra-
tory role seems to be specific for IL-13. Second, we
determined that EC tube formation in an in vitro
capillary morphogenesis assay was not seen with
AxCAIL-13 (Figure 1C), suggesting that IL-13 inhibits
EC differentiation and results in less blood vessel growth
in vivo. Third, we confirmed these findings in the rat
aortic ring assay (Figures 2A and B), in which both EC
migration and differentiation take place. While signifi-
cant sprouting occurred in response to joint homoge-
nates from the PBS and AxCANI groups, IL-13 gene
delivery resulted in significantly less sprout formation.
Fourth, to determine if IL-13 exerts its angiostatic role
in vivo, we tested the ability of rat AIA homogenates to
induce blood vessel penetration and formation in an in
vivo Matrigel plug angiogenesis assay (Figure 2C). In
vivo blood vessel growth was significantly inhibited in
response to AxCAIL-13 homogenates, which corrobo-
rated previous histologic data (7).
These results provide direct evidence that IL-13
is able to inhibit important steps in neovascularization,
namely, EC migration and differentiation, as well as
blood vessel formation, in vivo.
Next, using whole joint homogenates, we identi-
fied signal transduction pathways associated with IL-13–
mediated inhibition of inflammation and angiogenesis
(29,44) (Figure 3 and Table 1). The MAPK pathway has
been implicated in IL-13–induced signaling via IRS-1
and IRS-2 (45), and we hypothesized that signaling
cross-talk among MAPKs and other signaling molecules
may play an important role in IL-13–mediated angiosta-
tic effects. We observed a strong phosphorylation of
ERK-1/2, but not p38 MAPK or JNK1/2. Up-regulation
of *p–ERK-1/2 was independent of the JAK/STAT6
pathway. However, using immunoprecipitation, we dis-
covered an association between ERK-1/2 and PKC/II
in response to IL-13 gene therapy, pointing to a novel
mechanism of IL-13 signaling. Up-regulation of *p-Raf
supports the notion that the ERK-1/2 pathway is acti-
vated by IL-13 in vivo.
The biologic function of MAPK pathways in this
context, however, remains unclear. Only very recently
has ERK-1/2 been shown to mediate IL-13–induced lung
inflammation and remodeling in vivo (11). Consistent
with our results, the selective stimulation of ERK-1/2
was found to be independent of STAT6 (11). In the
current study, we showed that *p–NF-B p65 was down-
regulated by AxCAIL-13. This is of importance since
NF-B not only has proinflammatory properties (46),
but its activation can also mediate angiogenesis, for
example, by up-regulating proangiogenic cytokines,
growth factors, and MMPs (47). Thus, decreased expres-
sion of *p–NF-B p65 may promote inhibition of neo-
vascularization. Our findings further suggest that IL-13
may exert its antiangiogenic function in vivo via activa-
tion of PKC/II and ERK-1/2, with concomitant down-
regulation of the NF-B p65 pathway (Figure 6).
To determine whether IL-13 treatment changes
the balance between pro- and antiinflammatory factors
in vivo, we determined protein expression of select
cytokines in the homogenates (Figure 4). LIX/CXCL5,
the rat homolog of the proangiogenic chemokine ENA-
78/CXCL5, was strongly down-regulated by AxCAIL-13.
This is consistent with our previous data, showing that
ENA-78/CXCL5 accounted for a significant proportion
of the chemotactic activity for ECs as well as angiogenic
activity in RA synovial tissue homogenates (48). Like-
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wise, levels of CINC-1/CXCL1 were significantly lower
in the AxCAIL-13 group, which corroborates the ability
of the human homologs of CINC-1, GRO/CXCL1, to
promote angiogenesis (49). IL-18, a proangiogenic cyto-
kine (23), was significantly down-regulated in response
to IL-13 gene therapy in vivo, while there was no change
in the expression of either IL-6 or the potent angiogenic
chemokines CXCL16 and fractalkine/CX3CL1 (50,51).
Increased expression of TGF, which is known to play a
dual role in neovascularization (52,53), suggests an
antiangiogenic role in response to IL-13, possibly via the
activin receptor–like kinase 5/Smad2/3 pathway (54). In
contrast, endostatin, a powerful angiogenesis inhibitor in
vitro and in vivo (55), was up-regulated as compared
with the vector control.
Since gelatinases are important regulators and
modifiers of angiogenesis, we determined whether IL-13
gene therapy altered MMP-2 and MMP-9 expression
and activity (Figure 5). Reduced expression and gela-
tinolytic activity of both MMPs in rat AIA joint homog-
enates in response to IL-13 pointed to another possible
angiostatic mechanism. This is in contrast to MMP-2 and
MMP-9 up-regulation by IL-13 in the murine lung that
has been described (56). However, IL-13–associated
effects might be differentially modulated in this type
2–polarized environment or in the context of angiogenesis.
In conclusion, we have shown that 1) IL-13 gene
therapy inhibits angiogenesis in arthritis in vivo, 2) IL-13
activates a novel signaling pathway via PKC/II and
ERK-1/2 in vivo, 3) IL-13–mediated angiostatic effects
in vivo are associated with an altered balance of pro- and
antiangiogenic cytokines, and 4) IL-13 may exert its
Figure 6. Schematic model of interleukin-13 (IL-13)–induced angiostatic effects in vivo. IL-13 activates
insulin receptor substrate 1/2 (IRS-1/2), which in turn, activates ERK-1/2, either directly or via protein
kinase C/II (PKC/II). ERK-1/2 phosphorylation (P) possibly down-regulates NF-B phosphorylation
and impairs subsequent translocation to the nucleus, thereby governing the transcription of inducers and
inhibitors of angiogenesis. Alternatively, ERK-1/2 may act via other transcription factors known to be
downstream, such as activator protein 1 (AP-1). Another possibility is that IL-13 signals via the
JAK/STAT6 pathway, initially activating Tyk2 and JAK1. STAT6 translocation possibly also shifts the
balance between pro- and antiangiogenic factors. Solid arrows represent known mechanisms; broken
arrows represent hypothesized mechanisms. IL-13r1  IL-13 receptor 1; CINC-1  cytokine-induced
neutrophil chemoattractant 1; LIX  lipopolysaccharide-induced CXC chemokine; MMP-2  matrix
metalloproteinase 2; TGF  transforming growth factor .
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antiangiogenic effects in part by down-regulating
MMP-2 and MMP-9. This study shows that IL-13 gene
therapy is a useful approach to the reduction of neovas-
cularization in arthritis in vivo. Knowledge of the spe-
cific angiostatic role of IL-13 may help to optimize
therapeutic opportunities in the targeting of pathologic
blood vessel growth, a condition central to the pathology
of RA.
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